Outcomes for hypopharyngeal carcinoma treated with organ-preservation therapy

Mark A. Edson; Adam S. Garden; Vinita Takiar; Bonnie S. Glisson; Clifton D. Fuller; Gary B. Gunn; Beth M. Beadle; William H. Morrison; Steven J. Frank; Shalin J. Shah; Randa Tao; William N. William; Randal S. Weber; David I. Rosenthal; Jack Phan

doi:10.1002/hed.24387

Outcomes for hypopharyngeal carcinoma treated with organ-preservation therapy

Mark A. Edson, Adam S. Garden, Vinita Takiar, Bonnie S. Glisson, Clifton D. Fuller, Gary B. Gunn, Beth M. Beadle, William H. Morrison, Steven J. Frank, Shalin J. Shah, Randa Tao, William N. William, Randal S. Weber, David I. Rosenthal, Jack Phan

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Background This study assessed outcomes of patients with hypopharyngeal carcinoma treated with organ-preservation therapy utilizing intensity-modulated radiation therapy (IMRT). Methods The medical records of 98 patients treated with definitive IMRT +/- chemotherapy from 2001 to 2013 for nonmetastatic hypopharyngeal cancer were retrospectively reviewed. Results Patients were treated to doses of 66 to 72 Gy. Eighty-three patients (85%) received chemotherapy. With median follow-up of 35 months, 2-year overall survival (OS), locoregional control, progression-free survival (PFS), and laryngectomy-free survival rates were 74%, 77%, 67%, and 65%, respectively. Functional laryngeal preservation rate was 76% at 2 years. N3 disease correlated with worse OS (p <.01). Concurrent chemotherapy correlated with improved locoregional control (p =.03) and complete response to induction chemotherapy correlated with improved OS and PFS (p =.02). Actuarial 2-year and 5-year grade 3 treatment toxicities were 17% and 21%, respectively. Conclusion Favorable disease outcomes and functional laryngeal preservation rates can be achieved with IMRT for patients with hypopharyngeal cancer.

Original language	English (US)
Pages (from-to)	E2091-E2099
Journal	Head and Neck
Volume	38
DOIs	https://doi.org/10.1002/hed.24387
State	Published - Apr 1 2016

Keywords

hypopharyngeal carcinoma
intensity-modulated radiotherapy (IMRT)
laryngeal preservation
toxicities

ASJC Scopus subject areas

Otorhinolaryngology

Access to Document

10.1002/hed.24387

Cite this

@article{02bce70a7b6e409b8dca77658040fe1c,

title = "Outcomes for hypopharyngeal carcinoma treated with organ-preservation therapy",

abstract = "Background This study assessed outcomes of patients with hypopharyngeal carcinoma treated with organ-preservation therapy utilizing intensity-modulated radiation therapy (IMRT). Methods The medical records of 98 patients treated with definitive IMRT +/- chemotherapy from 2001 to 2013 for nonmetastatic hypopharyngeal cancer were retrospectively reviewed. Results Patients were treated to doses of 66 to 72 Gy. Eighty-three patients (85%) received chemotherapy. With median follow-up of 35 months, 2-year overall survival (OS), locoregional control, progression-free survival (PFS), and laryngectomy-free survival rates were 74%, 77%, 67%, and 65%, respectively. Functional laryngeal preservation rate was 76% at 2 years. N3 disease correlated with worse OS (p <.01). Concurrent chemotherapy correlated with improved locoregional control (p =.03) and complete response to induction chemotherapy correlated with improved OS and PFS (p =.02). Actuarial 2-year and 5-year grade 3 treatment toxicities were 17% and 21%, respectively. Conclusion Favorable disease outcomes and functional laryngeal preservation rates can be achieved with IMRT for patients with hypopharyngeal cancer.",

keywords = "hypopharyngeal carcinoma, intensity-modulated radiotherapy (IMRT), laryngeal preservation, toxicities",

author = "Edson, {Mark A.} and Garden, {Adam S.} and Vinita Takiar and Glisson, {Bonnie S.} and Fuller, {Clifton D.} and Gunn, {Gary B.} and Beadle, {Beth M.} and Morrison, {William H.} and Frank, {Steven J.} and Shah, {Shalin J.} and Randa Tao and William, {William N.} and Weber, {Randal S.} and Rosenthal, {David I.} and Jack Phan",

note = "Publisher Copyright: {\textcopyright} 2015 Wiley Periodicals, Inc..",

year = "2016",

month = apr,

day = "1",

doi = "10.1002/hed.24387",

language = "English (US)",

volume = "38",

pages = "E2091--E2099",

journal = "Head and Neck",

issn = "1043-3074",

publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Outcomes for hypopharyngeal carcinoma treated with organ-preservation therapy

AU - Edson, Mark A.

AU - Garden, Adam S.

AU - Takiar, Vinita

AU - Glisson, Bonnie S.

AU - Fuller, Clifton D.

AU - Gunn, Gary B.

AU - Beadle, Beth M.

AU - Morrison, William H.

AU - Frank, Steven J.

AU - Shah, Shalin J.

AU - Tao, Randa

AU - William, William N.

AU - Weber, Randal S.

AU - Rosenthal, David I.

AU - Phan, Jack

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Background This study assessed outcomes of patients with hypopharyngeal carcinoma treated with organ-preservation therapy utilizing intensity-modulated radiation therapy (IMRT). Methods The medical records of 98 patients treated with definitive IMRT +/- chemotherapy from 2001 to 2013 for nonmetastatic hypopharyngeal cancer were retrospectively reviewed. Results Patients were treated to doses of 66 to 72 Gy. Eighty-three patients (85%) received chemotherapy. With median follow-up of 35 months, 2-year overall survival (OS), locoregional control, progression-free survival (PFS), and laryngectomy-free survival rates were 74%, 77%, 67%, and 65%, respectively. Functional laryngeal preservation rate was 76% at 2 years. N3 disease correlated with worse OS (p <.01). Concurrent chemotherapy correlated with improved locoregional control (p =.03) and complete response to induction chemotherapy correlated with improved OS and PFS (p =.02). Actuarial 2-year and 5-year grade 3 treatment toxicities were 17% and 21%, respectively. Conclusion Favorable disease outcomes and functional laryngeal preservation rates can be achieved with IMRT for patients with hypopharyngeal cancer.

AB - Background This study assessed outcomes of patients with hypopharyngeal carcinoma treated with organ-preservation therapy utilizing intensity-modulated radiation therapy (IMRT). Methods The medical records of 98 patients treated with definitive IMRT +/- chemotherapy from 2001 to 2013 for nonmetastatic hypopharyngeal cancer were retrospectively reviewed. Results Patients were treated to doses of 66 to 72 Gy. Eighty-three patients (85%) received chemotherapy. With median follow-up of 35 months, 2-year overall survival (OS), locoregional control, progression-free survival (PFS), and laryngectomy-free survival rates were 74%, 77%, 67%, and 65%, respectively. Functional laryngeal preservation rate was 76% at 2 years. N3 disease correlated with worse OS (p <.01). Concurrent chemotherapy correlated with improved locoregional control (p =.03) and complete response to induction chemotherapy correlated with improved OS and PFS (p =.02). Actuarial 2-year and 5-year grade 3 treatment toxicities were 17% and 21%, respectively. Conclusion Favorable disease outcomes and functional laryngeal preservation rates can be achieved with IMRT for patients with hypopharyngeal cancer.

KW - hypopharyngeal carcinoma

KW - intensity-modulated radiotherapy (IMRT)

KW - laryngeal preservation

KW - toxicities

UR - http://www.scopus.com/inward/record.url?scp=84959422903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959422903&partnerID=8YFLogxK

U2 - 10.1002/hed.24387

DO - 10.1002/hed.24387

M3 - Article

C2 - 26920665

AN - SCOPUS:84959422903

SN - 1043-3074

VL - 38

SP - E2091-E2099

JO - Head and Neck

JF - Head and Neck

ER -

Outcomes for hypopharyngeal carcinoma treated with organ-preservation therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this